The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmsc 5.25% Regulatory News (AG99)

Share Price Information for Glaxosmsc 5.25% (AG99)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 103.525
Bid: 101.50
Ask: 104.65
Change: 0.00 (0.00%)
Spread: 3.15 (3.103%)
Open: 103.525
High: 0.00
Low: 0.00
Prev. Close: 103.525
AG99 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Optional Redemption

28 Sep 2020 15:40

RNS Number : 3394A
GlaxoSmithKline Capital PLC
28 September 2020
 

 

Issued: September 28, 2020

 

NOTICE OF OPTIONAL REDEMPTION

 

GLAXOSMITHKLINE CAPITAL PLC

3.125% Notes Due 2021

CUSIP No: 377373 AE5 ISIN No: US377373AE54* (the "Notes")

 

September 28, 2020

 

 

To: The Holders of the Notes

The New York Stock Exchange

 

NOTE: THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED HOLDERS AND BENEFICIAL OWNERS OF THE NOTES. IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS, AND OTHER INTERMEDIARIES RECEIVING THIS NOTICE ARE REQUESTED TO EXPEDITE RE-TRANSMITTAL TO THE REGISTERED HOLDERS AND BENEFICIAL OWNERS OF THE NOTES IN A TIMELY MANNER.

 

The Notes were issued pursuant to an indenture dated as of April 6, 2004 among GlaxoSmithKline Capital plc, a public limited company incorporated and registered in England and Wales, as issuer (the "Issuer"), GlaxoSmithKline plc, a public limited company incorporated and registered in England and Wales, as guarantor (the "Guarantor") and Deutsche Bank Trust Company Americas as trustee (as successor to Law Debenture Trust Company of New York, pursuant to an Instrument of Resignation, Appointment and Acceptance dated April 12, 2017, among the Issuer, Law Debenture Trust Company of New York and Deutsche Bank Trust Company Americas, the "Trustee") (the "Base Indenture" and, as amended and supplemented by a first supplemental indenture, dated as of March 21, 2014 and as further amended and supplemented by a second supplemental indenture dated as of May 15, 2018, the "Indenture"). Capitalized terms used and not defined herein have the meanings ascribed to them in the Indenture or, if not defined therein, the Notes.

 

NOTICE IS HEREBY GIVEN that, pursuant to Section 3.02 of the Indenture, the Issuer has elected to redeem and will redeem on October 13, 2020 (the "Redemption Date") all of the remaining principal amount of the Notes outstanding at the Redemption Price (defined below).

 

The "Redemption Price" shall mean an amount equal to the greater of:

 

(A) 100% of the principal amount of the Notes

 

OR

 

(B) as determined by the Quotation Agent, the sum of the present values of the Remaining Scheduled Payments, discounted to the Redemption Date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 0.100%,

 

plus 

 

in either of the above cases, accrued and unpaid interest thereon to, but excluding, the Redemption Date.

 

Holders of the Notes will be paid the Redemption Price upon presentation and surrender of their Notes for redemption at the following addresses:

 

By mail or overnight courier:

 

DB Services Americas, Inc

5022 Gate Parkway Suite 200

MS JCK01-0218

Jacksonville, FL 32256

 

For Information call 1-800-735-7777

 

 

Upon receipt of funds for such purpose from the Issuer, the Trustee shall pay, in immediately available funds, the Redemption Price of such Notes to the registered Holder of all Notes outstanding, Cede & Co., the nominee for The Depository Trust Company ("DTC"), in accordance with applicable DTC procedures.

On the Redemption Date, (i) the Redemption Price will become due and payable on the Notes, (ii) unless the Company defaults in making payment of the Redemption Price, interest on the Notes shall cease to accrue on and after the Redemption Date and (iii) the only remaining right of the holder with respect to the Notes will be to receive payment of the Redemption Price upon surrender to the Trustee.

*No representation is made as to the correctness of the CUSIP or ISIN number either as printed on the Notes or as contained in this Notice of Redemption and the holder should rely only on the other identification numbers printed on the Notes. This CUSIP number has been assigned to this issue by Standard and Poor's Corporation and is included solely for the convenience of the holders. Neither the Issuer, the Trustee nor the Paying Agent or any of their agents shall be responsible for the selection or use of this CUSIP number, nor is any representation made as to its correctness on the bonds or as indicated in any redemption notice.

 

IMPORTANT TAX INFORMATION

 

EXISTING FEDERAL INCOME TAX LAW MAY REQUIRE BACKUP WITHHOLDING OF 24% OF ANY PAYMENTS TO HOLDERS PRESENTING THEIR SECURITIES FOR PAYMENTS WHO HAVE FAILED TO FURNISH A TAXPAYER IDENTIFICATION NUMBER, CERTIFIED TO BE CORRECT UNDER PENALTY OF PERJURY ON A COMPLETE AND VALID INTERNAL REVENUE SERVICE ("IRS") FORM W-9 OR APPLICABLE FORM W-8 TO THE APPLICABLE PAYER OR WITHHOLDING AGENT. HOLDERS MAY ALSO BE SUBJECT TO A PENALTY OF $50.00 FOR FAILURE TO PROVIDE SUCH NUMBER.

 

Sincerely,

 

 

GLAXOSMITHKLINE CAPITAL PLC

 

By: Deutsche Bank Trust Company Americas, as Trustee

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPURWBUPUGCR
12
Date   Source Headline
20th Dec 20234:44 pmRNSPublication of EMTN Suppl.Prospcts
19th Sep 20233:01 pmRNSEMTN Programme issue - publication of Final Terms
8th Aug 20231:05 pmRNSPublication of Base Prospectus
31st Jul 20234:57 pmRNSHalf-year Report
28th Apr 20235:09 pmRNSAnnual Financial Report
13th Feb 20235:35 pmRNSEMTN Notes repurchase results
22nd Nov 20224:00 pmRNSPublication of Supplementary EMTN Prospectus
18th Nov 20224:00 pmRNSPublication of EMTN Supplementary Prospectus
15th Nov 20223:53 pmRNSFinal results of outstanding Notes Tender Offer
15th Nov 20227:00 amRNSInterim results of outstanding Notes Tender Offer
8th Nov 20229:26 amRNSLaunch of Tender Offer for outstanding Notes
3rd Nov 20221:00 pmRNSPublication of Suppl.Prospcts
9th Sep 20229:11 amRNSPublication of Base Prospectus
2nd Aug 202212:51 pmRNSHalf-year Report
29th Apr 20221:00 pmRNSAnnual Financial Report
14th Apr 20222:30 pmRNSNotice of Optional Redemption
8th Dec 20211:35 pmRNSPublication of a Prospectus
29th Jul 202110:23 amRNSHalf-year Report
11th May 202111:30 amRNSEMTN Prospectus
22nd Apr 202111:21 amRNSAnnual Financial Report
26th Nov 202012:38 pmRNSEMTN Supplementary Prospectus
28th Sep 20203:40 pmRNSNotice of Optional Redemption
4th Aug 20206:30 pmRNSPublication of a Prospectus
31st Jul 20202:02 pmRNSReplacement: Half-year Report
29th Jul 20205:01 pmRNSHalf-year Report
7th May 20205:43 pmRNSPublication of Final Terms
5th May 20208:06 amRNSStabilisation Notice
4th May 202010:41 amRNSStabilisation Notice
30th Apr 20206:09 pmRNSAnnual Financial Report
30th Apr 20205:51 pmRNSPublication of a Prospectus
13th Mar 20205:32 pmRNSEMTN Prospectus Supplement Update
16th Oct 20199:43 amRNSPost Stabilisation Notice - GlaxoSmithKline
19th Sep 20193:37 pmRNSEMTN Programme Issuance of Bonds
16th Sep 20198:31 amRNSPre Stabilisation Notice - GlaxoSmithKline Capital
2nd Aug 20195:34 pmRNSPublication of Base Prospectus
24th Jul 20195:30 pmRNSGlaxoSmithKline Capital plc Half Yearly Report
26th Apr 201911:04 amRNSFinal Results
2nd Aug 20185:07 pmRNSPublication of Base Prospectus
26th Jul 20182:19 pmRNSHalf-year Report
17th May 20184:10 pmRNSPublication of Final Terms
11th May 201812:33 pmRNSPublication of Supplementary Prospectus
12th Apr 20183:01 pmRNSAnnual Financial Report
8th Sep 20174:39 pmRNSPublication of Final Terms
5th Sep 201710:19 amRNSStabilisation Notice
28th Jul 20174:45 pmRNSHalf-year Report
27th Apr 20174:26 pmRNSAnnual Financial Report
4th Aug 20163:50 pmRNSPublication of a Prospectus
27th Jul 20163:52 pmRNSHalf-year Report
26th Apr 20164:09 pmRNSAnnual Financial Report
4th Aug 20152:34 pmRNSPublication of Prospectus
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.